Clinical Trial

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate. The investigators want to find out if this new test is better to detect prostate cancer than just doing a biopsy based on MRI alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-22; most recent amendment 2026-04-09.
Status change: Active, Not Recruiting → Recruiting 2026-04-09
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-04
Trial Details
NCT Number NCT07220720
Lead Sponsor University of Florida
Conditions Prostate
Enrollment 30 participants
Start Date 2025-11-04
Primary Completion 2030-07-15 (estimated)
Study Completion 2032-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-13